MIFH
DRNA

Migdal Insurance & Financial Holdings’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-27,455
Closed -$702K – 695
2021
Q1 		$702K Buy
27,455
+17,038
+164% +$435K 0.01% 280
2020
Q4 		$229K Buy
+10,417
New +$229K ﹤0.01% 302

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Migdal Insurance & Financial Holdings's DRNA Position: Q2 2021 in Review

Migdal Insurance & Financial Holdings sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2021, closing a stake of 27,455 shares — an estimated $702K sold.

Migdal Insurance & Financial Holdings first reported a position in DRNA in Q4 2020 and held it in 2 quarters. The position peaked at $702K in Q1 2021. 203 funds tracked by Wall St. Rank hold DRNA as of Q2 2021.

  • Migdal Insurance & Financial Holdings reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 27,455 Dicerna Pharmaceuticals, Inc. shares in Q2 2021, an estimated $702K.
  • Migdal Insurance & Financial Holdings first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2020 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Dicerna Pharmaceuticals, Inc. position peaked at $702K in Q1 2021.
  • 203 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2021.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2021, filed 4 Aug 2021.